
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is a clinical-stage biopharmaceutical company that is dedicated to improving the lives of patients with mental health disorders. Their focus on developing novel and proprietary treatments for Treatment-Resistant Depression, or TRD, shows a strong potential for success in a field with limited treatment options. With a completed enrollment in Phase 3 pivotal program and a strong pipeline portfolio, GH Research has demonstrated effective execution in moving their promising therapy forward.
Bears say
GH Research is facing several fundamental risks that could negatively impact its stock outlook. These include potential issues with FDA lifting the clinical hold on GH001, as well as the potential for the registrational Phase 3 study to not replicate the efficacy seen in earlier trials. Additionally, there are potential safety and tolerability concerns that could lead to the study being halted. Furthermore, there may be competition from other more efficacious products in the market, and the company may struggle to secure financing for the Phase 3 trial or for commercialization should GH001 be approved.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares